1,793 results on '"Wei, John T"'
Search Results
2. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium
- Author
-
Chang, Peter, Wagner, Andrew A, Regan, Meredith M, Smith, Joseph A, Saigal, Christopher S, Litwin, Mark S, Hu, Jim C, Cooperberg, Matthew R, Carroll, Peter R, Klein, Eric A, Kibel, Adam S, Andriole, Gerald L, Han, Misop, Partin, Alan W, Wood, David P, Crociani, Catrina M, Greenfield, Thomas K, Patil, Dattatraya, Hembroff, Larry A, Davis, Kyle, Stork, Linda, Spratt, Daniel E, Wei, John T, Sanda, Martin G, and Consortium, and the PROST-QA RP2
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Pain Research ,Chronic Pain ,Urologic Diseases ,Cancer ,6.4 Surgery ,Evaluation of treatments and therapeutic interventions ,Aged ,Humans ,Laparoscopy ,Male ,Middle Aged ,Prospective Studies ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Robotic Surgical Procedures ,Treatment Outcome ,prostatectomy ,robotic surgical procedures ,quality of life ,PROST-QA/RP2 Consortium - Abstract
PurposeOur goal was to evaluate the comparative effectiveness of robot-assisted laparoscopic prostatectomy (RALP) and open radical prostatectomy (ORP) in a multicenter study.Materials and methodsWe evaluated men with localized prostate cancer at 11 high-volume academic medical centers in the United States from the PROST-QA (2003-2006) and the PROST-QA/RP2 cohorts (2010-2013) with a pre-specified goal of comparing RALP (549) and ORP (545). We measured longitudinal patient-reported health-related quality of life (HRQOL) at pre-treatment and at 2, 6, 12, and 24 months, and pathological and perioperative outcomes/complications.ResultsDemographics, cancer characteristics, and margin status were similar between surgical approaches. ORP subjects were more likely to undergo lymphadenectomy (89% vs 47%; p
- Published
- 2022
3. Expanded Prostate Cancer Index Composite (EPIC)
- Author
-
Schroeck, Florian R., Wei, John T., Tognetti, Mara, Section editor, and Maggino, Filomena, editor
- Published
- 2023
- Full Text
- View/download PDF
4. Intra-practice Urologist-level Variation in Targeted Fusion Biopsy Outcomes
- Author
-
Dhir, Apoorv, Ellimoottil, Chad S., Qi, Ji, Zhu, Alex, Wang, Robert S., Montgomery, Jeffrey S., Salami, Simpa S., Wei, John T., Shankar, Prasad R., Davenport, Matthew S., Curci, Nicole E., Millet, John D., Wu, Chen-Yu, Johnson, Anna, Miller, David C., and George, Arvin K.
- Published
- 2023
- Full Text
- View/download PDF
5. MP12-05 RELATIVE IMPACT OF URINARY CONDITIONS ON OVERALL QUALITY OF LIFE
- Author
-
Vasudevan, Vishrudh, primary, Dunn, Rodney L., additional, Miner, Martin, additional, Roehrborn, Claus, additional, Seftel, Allen, additional, Spino, Cathie, additional, Wei, John T., additional, and Sarma, Aruna, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Assessment of prostate cancer progression using a translational needle photoacoustic sensing probe: Preliminary study with intact human prostates ex-vivo
- Author
-
Ni, Linyu, Lin, Wei-kuan, Kasputis, Amy, Postiff, Deborah, Siddiqui, Javed, Allaway, Matthew J., Davenport, Matthew S., Wei, John T., Guo, Jay L., Morgan, Todd M., Udager, Aaron M., Wang, Xueding, and Xu, Guan
- Published
- 2022
- Full Text
- View/download PDF
7. Two Specialists, Two Recommendations: Discordance Between Urologists’ & Radiation Oncologists’ Prostate Cancer Treatment Recommendations
- Author
-
Delaney, Rebecca K., Sisco-Taylor, Brittany L., Wang, Xuechen, Scherr, Karen, Ubel, Peter A., Haaland, Benjamin, Kahn, Valerie C., Hamstra, Daniel, Wei, John T., Madanay, Farrah, Davis, J. Kelly, Greeno, Taylor U., and Fagerlin, Angela
- Published
- 2022
- Full Text
- View/download PDF
8. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer
- Author
-
Cani, Andi K., Hu, Kevin, Liu, Chia-Jen, Siddiqui, Javed, Zheng, Yingye, Han, Sumin, Nallandhighal, Srinivas, Hovelson, Daniel H., Xiao, Lanbo, Pham, Trinh, Eyrich, Nicholas W., Zheng, Heng, Vince, Randy, Jr, Tosoian, Jeffrey J., Palapattu, Ganesh S., Morgan, Todd M., Wei, John T., Udager, Aaron M., Chinnaiyan, Arul M., Tomlins, Scott A., and Salami, Simpa S.
- Published
- 2022
- Full Text
- View/download PDF
9. Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
- Author
-
Zhang, Yajia, Pitchiaya, Sethuramasundaram, Cieślik, Marcin, Niknafs, Yashar S, Tien, Jean C-Y, Hosono, Yasuyuki, Iyer, Matthew K, Yazdani, Sahr, Subramaniam, Shruthi, Shukla, Sudhanshu K, Jiang, Xia, Wang, Lisha, Liu, Tzu-Ying, Uhl, Michael, Gawronski, Alexander R, Qiao, Yuanyuan, Xiao, Lanbo, Dhanasekaran, Saravana M, Juckette, Kristin M, Kunju, Lakshmi P, Cao, Xuhong, Patel, Utsav, Batish, Mona, Shukla, Girish C, Paulsen, Michelle T, Ljungman, Mats, Jiang, Hui, Mehra, Rohit, Backofen, Rolf, Sahinalp, Cenk S, Freier, Susan M, Watt, Andrew T, Guo, Shuling, Wei, John T, Feng, Felix Y, Malik, Rohit, and Chinnaiyan, Arul M
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Cancer ,Prostate Cancer ,Genetics ,Aging ,Urologic Diseases ,Aetiology ,2.1 Biological and endogenous factors ,Androgens ,Cell Line ,Tumor ,Disease Progression ,Gene Expression Regulation ,Neoplastic ,Humans ,Male ,Prostate ,Prostatic Neoplasms ,RNA ,Long Noncoding ,Receptors ,Androgen ,Signal Transduction ,Medical and Health Sciences ,Developmental Biology ,Agricultural biotechnology ,Bioinformatics and computational biology - Abstract
The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.
- Published
- 2018
10. Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
- Author
-
Tosoian, Jeffrey J., Dunn, Rodney L., Niknafs, Yashar S., Saha, Anjan, Vince, Randy A., Jr, St. Sauver, Jennifer L., Jacobson, Debra J., McGree, Michaela E., Siddiqui, Javed, Groskopf, Jack, Jacobsen, Steven J., Tomlins, Scott A., Kunju, Lakshmi P., Morgan, Todd M., Salami, Simpa S., Wei, John T., Chinnaiyan, Arul M., and Sarma, Aruna V.
- Published
- 2021
- Full Text
- View/download PDF
11. Development and Validation of a Quantitative Measure of Adaptive Behaviors in Women With Pelvic Floor Disorders.
- Author
-
Wei, John T, Dunn, Rodney, Nygaard, Ingrid, Burgio, Kathryn, Lukacz, Emily S, Markland, Alayne, Wren, Patricia A, Brubaker, Linda, Barber, Matthew D, Jelovsek, J Eric, Spino, Cathie, Meikle, Susie, Janz, Nancy, and PFDN
- Subjects
PFDN - Abstract
To establish validity for the Pelvic Floor Disorders Network (PFDN) self-administered Adaptive Behavior Index (ABI) and to assess whether ABI assesses known discordance between severity of pelvic floor symptoms and self-reported bother.In addition to the ABI questionnaire, participants in 1 of 6 Pelvic Floor Disorders Network trials completed condition-specific measures of pretreatment symptom severity (including Pelvic Floor Distress Inventory; PFDI) and health-related quality of life (Pelvic Floor Impact Questionnaire; PFIQ). The final survey was developed from an iterative process using subject and expert endorsement, factor analyses, and response distributions. Domains were created using a development cohort (n = 304 women), reliability and validity were established using a validation cohort (n = 596 women), and test-retest reliability was assessed (n = 111 women).Factor analyses supported an 11-item avoidance domain and a 6-item hygiene domain. Cronbach' alphas were 0.88 and 0.68, respectively. Test-retest reliability was 0.84 for both domains. Construct validity was demonstrated in correlations between the ABI domains and baseline PFDI and PFIQ (r values, 0.43-0.79 with all P values
- Published
- 2017
12. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
- Author
-
Loeb, Stacy, Shin, Sanghyuk S, Broyles, Dennis L, Wei, John T, Sanda, Martin, Klee, George, Partin, Alan W, Sokoll, Lori, Chan, Daniel W, Bangma, Chris H, Schaik, Ron HN, Slawin, Kevin M, Marks, Leonard S, and Catalona, William J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Aging ,Prostate Cancer ,Clinical Research ,Urologic Diseases ,Cancer ,Patient Safety ,Good Health and Well Being ,Biopsy ,Needle ,Decision Support Techniques ,Digital Rectal Examination ,Early Detection of Cancer ,Humans ,Male ,Middle Aged ,Neoplasm Grading ,Prospective Studies ,Prostate ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Risk Assessment ,Prostate Health Index ,prostate cancer ,risk assessment ,nomogram ,prostate biopsy ,Urology & Nephrology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
ObjectiveTo examine the use of the Prostate Health Index (PHI) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study.Materials and methodsThe study population included 728 men, with prostate-specific antigen (PSA) levels of 2-10 ng/mL and a negative digital rectal examination, enrolled in a prospective, multi-site early detection trial. The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score ≥7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [PCPT] and European Randomised Study of Screening for Prostate Cancer [ERSPC] risk calculators). We also designed and internally validated a new PHI-based multivariable predictive model, and created a nomogram.ResultsOf 728 men undergoing biopsy, 118 (16.2%) had aggressive prostate cancer. The PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Adding PHI significantly improved the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease. A new model was created using age, previous biopsy, prostate volume, PSA and PHI, with an area under the curve of 0.746. The bootstrap-corrected model showed good calibration with observed risk for aggressive prostate cancer and had net benefit on decision-curve analysis.ConclusionUsing PHI as part of multivariable risk assessment leads to a significant improvement in the detection of aggressive prostate cancer, potentially reducing harms from unnecessary prostate biopsy and overdiagnosis.
- Published
- 2017
13. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life
- Author
-
Gay, Hiram A, Sanda, Martin G, Liu, Jingxia, Wu, Ningying, Hamstra, Daniel A, Wei, John T, Dunn, Rodney L, Klein, Eric A, Sandler, Howard M, Saigal, Christopher S, Litwin, Mark S, Kuban, Deborah A, Hembroff, Larry, Regan, Meredith M, Chang, Peter, Consortium, Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment, Regan, Meredith, Hamstra, Dan, Dunn, Rodney, Northouse, Laurel, Wood, David, Ciezki, Jay, Michalski, Jeff, Andriole, Gerald, Saigal, Christopher, Greenfield, Thomas, Pisters, Louis, Kuban, Deborah, Sandler, Howard, Hu, Jim, Kibel, Adam, Dahl, Douglas, Zietman, Anthony, Kaplan, Irving, Wagner, Andrew, and Michalski, Jeff M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Trials and Supportive Activities ,Aging ,Prostate Cancer ,Urologic Diseases ,Clinical Research ,Aged ,Aged ,80 and over ,Androgen Antagonists ,Body Weight ,Brachytherapy ,Breast ,Chi-Square Distribution ,Combined Modality Therapy ,Depression ,Erectile Dysfunction ,Fatigue ,Hot Flashes ,Humans ,Male ,Middle Aged ,Neoadjuvant Therapy ,Orgasm ,Penile Erection ,Prospective Studies ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Quality of Life ,Surveys and Questionnaires ,Time Factors ,Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeThe long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer.Methods and materialsWe analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ2 or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level.ResultsFor subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively.ConclusionsCompared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.
- Published
- 2017
14. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study
- Author
-
Macleod, Liam C, Ellis, William J, Newcomb, Lisa F, Zheng, Yingye, Brooks, James D, Carroll, Peter R, Gleave, Martin E, Lance, Raymond S, Nelson, Peter S, Thompson, Ian M, Wagner, Andrew A, Wei, John T, and Lin, Daniel W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Urologic Diseases ,Clinical Research ,Aging ,Prostate Cancer ,Prevention ,Aged ,Biopsy ,Humans ,Male ,Middle Aged ,Prospective Studies ,Prostate ,Prostatic Neoplasms ,Time Factors ,Watchful Waiting ,prostatic neoplasms ,prostate specific antigen ,body mass index ,biopsy ,watchful waiting ,Urology & Nephrology ,Clinical sciences - Abstract
PurposeDuring active surveillance for localized prostate cancer, the timing of the first surveillance biopsy varies. We analyzed the Canary PASS (Prostate Cancer Active Surveillance Study) to determine biopsy timing influence on rates of prostate cancer adverse reclassification at the first active surveillance biopsy.Materials and methodsOf 1,085 participants in PASS, 421 had fewer than 34% of cores involved with cancer and Gleason sum 6 or less, and thereafter underwent on-study active surveillance biopsy. Reclassification was defined as an increase in Gleason sum and/or 34% or more of cores with prostate cancer. First active surveillance biopsy reclassification rates were categorized as less than 8, 8 to 13 and greater than 13 months after diagnosis. Multivariable logistic regression determined association between reclassification and first biopsy timing.ResultsOf 421 men, 89 (21.1%) experienced reclassification at the first active surveillance biopsy. Median time from prostate cancer diagnosis to first active surveillance biopsy was 11 months (IQR 7.8-13.8). Reclassification rates at less than 8, 8 to 13 and greater than 13 months were 24%, 19% and 22% (p = 0.65). On multivariable analysis, compared to men biopsied at less than 8 months the OR of reclassification at 8 to 13 and greater than 13 months were 0.88 (95% CI 0.5,1.6) and 0.95 (95% CI 0.5,1.9), respectively. Prostate specific antigen density 0.15 or greater (referent less than 0.15, OR 1.9, 95% CI 1.1, 4.1) and body mass index 35 kg/m2 or greater (referent less than 25 kg/m2, OR 2.4, 95% CI 1.1,5.7) were associated with increased odds of reclassification.ConclusionsTiming of the first active surveillance biopsy was not associated with increased adverse reclassification but prostate specific antigen density and body mass index were. In low risk patients on active surveillance, it may be reasonable to perform the first active surveillance biopsy at a later time, reducing the overall cost and morbidity of active surveillance.
- Published
- 2017
15. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment
- Author
-
Chang, Peter, Regan, Meredith M, Ferrer, Montserrat, Guedea, Ferran, Patil, Dattatraya, Wei, John T, Hembroff, Larry A, Michalski, Jeff M, Saigal, Chris S, Litwin, Mark S, Hamstra, Daniel A, Kaplan, Irving D, Ciezki, Jay P, Klein, Eric A, Kibel, Adam S, Sandler, Howard M, Dunn, Rodney L, Crociani, Catrina M, Sanda, Martin G, and Consortium, PROST-QA
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prostate Cancer ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Renal and urogenital ,Aged ,Brachytherapy ,Cost of Illness ,Follow-Up Studies ,Humans ,Lower Urinary Tract Symptoms ,Male ,Middle Aged ,Prospective Studies ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Treatment Outcome ,prostatic neoplasms ,quality of life ,outcome assessment ,surveys and questionnaires ,patient-centered care ,PROST-QA Consortium ,Urology & Nephrology ,Clinical sciences - Abstract
PurposeHarms of prostate cancer treatment on urinary health related quality of life have been thoroughly studied. In this study we evaluated not only the harms but also the potential benefits of prostate cancer treatment in relieving the pretreatment urinary symptom burden.Materials and methodsIn American (1,021) and Spanish (539) multicenter prospective cohorts of men with localized prostate cancer we evaluated the effects of radical prostatectomy, external radiotherapy or brachytherapy in relieving pretreatment urinary symptoms and in inducing urinary symptoms de novo, measured by changes in urinary medication use and patient reported urinary bother.ResultsUrinary symptom burden improved in 23% and worsened in 28% of subjects after prostate cancer treatment in the American cohort. Urinary medication use rates before treatment and 2 years after treatment were 15% and 6% with radical prostatectomy, 22% and 26% with external radiotherapy, and 19% and 46% with brachytherapy, respectively. Pretreatment urinary medication use (OR 1.4, 95% CI 1.0-2.0, p = 0.04) and pretreatment moderate lower urinary tract symptoms (OR 2.8, 95% CI 2.2-3.6) predicted prostate cancer treatment associated relief of baseline urinary symptom burden. Subjects with pretreatment lower urinary tract symptoms who underwent radical prostatectomy experienced the greatest relief of pretreatment symptoms (OR 4.3, 95% CI 3.0-6.1), despite the development of deleterious de novo urinary incontinence in some men. The magnitude of pretreatment urinary symptom burden and beneficial effect of cancer treatment on those symptoms were verified in the Spanish cohort.ConclusionsMen with pretreatment lower urinary tract symptoms may experience benefit rather than harm in overall urinary outcome from primary prostate cancer treatment. Practitioners should consider the full spectrum of urinary symptom burden evident before prostate cancer treatment in treatment decisions.
- Published
- 2017
16. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
- Author
-
Newcomb, Lisa F, Thompson, Ian M, Boyer, Hilary D, Brooks, James D, Carroll, Peter R, Cooperberg, Matthew R, Dash, Atreya, Ellis, William J, Fazli, Ladan, Feng, Ziding, Gleave, Martin E, Kunju, Priya, Lance, Raymond S, McKenney, Jesse K, Meng, Maxwell V, Nicolas, Marlo M, Sanda, Martin G, Simko, Jeffry, So, Alan, Tretiakova, Maria S, Troyer, Dean A, True, Lawrence D, Vakar-Lopez, Funda, Virgin, Jeff, Wagner, Andrew A, Wei, John T, Zheng, Yingye, Nelson, Peter S, Lin, Daniel W, and Canary PASS Investigators
- Subjects
Canary PASS Investigators ,Humans ,Prostatic Neoplasms ,Biopsy ,Treatment Outcome ,Prostatectomy ,Tumor Burden ,Population Surveillance ,Risk Factors ,Prospective Studies ,Aged ,Middle Aged ,Male ,Watchful Waiting ,Neoplasm Grading ,Biomarkers ,Tumor ,prospective studies ,prostatic neoplasms ,watchful waiting ,Clinical Research ,Urologic Diseases ,Prostate Cancer ,Cancer ,Prevention ,Aging ,Patient Safety ,Clinical Sciences ,Urology & Nephrology - Abstract
PurposeActive surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance.Materials and methodsWe studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance.ResultsAt a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p=0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p=0.76).ConclusionsMost men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome.
- Published
- 2016
17. Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index
- Author
-
Osawa, Takahiro, Wei, John T., Abe, Takashige, Honda, Michitaka, Yamada, Shuhei, Furumido, Jun, Kikuchi, Hiroshi, Matsumoto, Ryuji, Hirakawa, Kazushi, Sato, Yasuyuki, Sasaki, Yoshihiro, Harabayashi, Toru, Takada, Norikata, Minami, Keita, Tanaka, Hiroshi, Morita, Ken, Kashiwagi, Akira, Miyajima, Naoto, Akino, Tomoshige, Murai, Sachiyo, Ito, Yoichi M., Fukuhara, Shunichi, Ogasawara, Katsuhiko, and Shinohara, Nobuo
- Published
- 2020
- Full Text
- View/download PDF
18. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator
- Author
-
Ankerst, Donna P, Xia, Jing, Thompson, Ian M, Hoefler, Josef, Newcomb, Lisa F, Brooks, James D, Carroll, Peter R, Ellis, William J, Gleave, Martin E, Lance, Raymond S, Nelson, Peter S, Wagner, Andrew A, Wei, John T, Etzioni, Ruth, and Lin, Daniel W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Clinical Research ,Aging ,Urologic Diseases ,Cancer ,Prostate Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Biomedical Research ,Biopsy ,Early Detection of Cancer ,Humans ,Male ,Middle Aged ,Precision Medicine ,Prospective Studies ,Prostatic Neoplasms ,Risk Assessment ,Watchful Waiting ,Active surveillance ,Progression ,Prostate-specific antigen ,Urology & Nephrology ,Clinical sciences - Abstract
BackgroundMen on active surveillance (AS) face repeated biopsies. Most biopsy specimens will not show disease progression or change management. Such biopsies do not contribute to patient management and are potentially morbid and costly.ObjectiveTo use a contemporary AS prospective trial to develop a tool to predict AS biopsy outcomes.Design, setting, and participantsBiopsy samples (median: 2; range: 2-9 per patient) from 859 men participating in the Canary Prostate Active Surveillance Study and with Gleason 6 prostate cancer (median follow-up: 35.8 mo; range: 3.0-148.7 mo) were analyzed.Outcome measurements and statistical analysisLogistic regression was used to predict progression, defined as an increase in Gleason score from ≤6 to ≥7 or increase in percentage of cores positive for cancer from
- Published
- 2015
19. Head to head randomized trial of two decision aids for prostate cancer
- Author
-
Fagerlin, Angela, Holmes-Rovner, Margaret, Hofer, Timothy P., Rovner, David, Alexander, Stewart C., Knight, Sara J., Ling, Bruce S., A.Tulsky, James, Wei, John T., Hafez, Khaled, Kahn, Valerie C., Connochie, Daniel, Gingrich, Jeffery, and Ubel, Peter A.
- Published
- 2021
- Full Text
- View/download PDF
20. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
- Author
-
Loeb, Stacy, Sanda, Martin G, Broyles, Dennis L, Shin, Sanghyuk S, Bangma, Chris H, Wei, John T, Partin, Alan W, Klee, George G, Slawin, Kevin M, Marks, Leonard S, van Schaik, Ron HN, Chan, Daniel W, Sokoll, Lori J, Cruz, Amabelle B, Mizrahi, Isaac A, and Catalona, William J
- Subjects
Cancer ,Clinical Research ,Prostate Cancer ,Aging ,Urologic Diseases ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Health Status Indicators ,Humans ,Male ,Middle Aged ,Prospective Studies ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Protein Precursors ,biological markers ,prostatic neoplasms ,early detection of cancer - Abstract
PurposeThe Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer over diagnosis.Materials and methodsFrom a multicenter prospective trial we identified 658 men age 50 years or older with prostate specific antigen 4 to 10 ng/ml and normal digital rectal examination who underwent prostate biopsy. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, [-2]proPSA and phi to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria.ResultsThe Prostate Health Index was significantly higher in men with Gleason 7 or greater and "Epstein significant" cancer. On receiver operating characteristic analysis phi had the highest AUC for overall prostate cancer (AUCs phi 0.708, percent free prostate specific antigen 0.648, [-2]proPSA 0.550 and prostate specific antigen 0.516), Gleason 7 or greater (AUCs phi 0.707, percent free prostate specific antigen 0.661, [-2]proPSA 0.558, prostate specific antigen 0.551) and significant prostate cancer (AUCs phi 0.698, percent free prostate specific antigen 0.654, [-2]proPSA 0.550, prostate specific antigen 0.549). At the 90% sensitivity cut point for phi (a score less than 28.6) 30.1% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free prostate specific antigen.ConclusionsThe new phi test outperforms its individual components of total, free and [-2]proPSA for the identification of clinically significant prostate cancer. Phi may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.
- Published
- 2015
21. A screening tool for clinically relevant urinary incontinence
- Author
-
Suskind, Anne M, Dunn, Rodney L, Morgan, Daniel M, DeLancey, John OL, Rew, Karl T, and Wei, John T
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Research ,Urologic Diseases ,Renal and urogenital ,Adult ,Area Under Curve ,Female ,Humans ,Michigan ,Middle Aged ,Predictive Value of Tests ,Prevalence ,Prognosis ,ROC Curve ,Sex Factors ,Surveys and Questionnaires ,Urinary Bladder ,Urinary Incontinence ,Urodynamics ,population ,quality of life ,receiver operating characteristic curve ,screening ,sensitivity ,specificity ,validation ,Clinical Sciences ,Neurosciences ,Urology & Nephrology ,Clinical sciences - Abstract
AimsThe Michigan Incontinence Symptom Index (M-ISI) is a validated measure for urinary incontinence. This study evaluates the M-ISI as a screening tool for clinically relevant urinary incontinence in a population-based sample of women.MethodsThe Establishing the Prevalence of Incontinence (EPI) Study is a case-control, population-based study that enrolled women ages 35-64, with and without urinary incontinence. The M-ISI is a validated questionnaire with subdomains for stress and urgency urinary incontinence. Two hundred fourteen EPI subjects underwent a clinical evaluation and urodynamic testing to establish the presence and type of urinary incontinence, and also completed the M-ISI. The M-ISI scores were evaluated using receiver operating characteristic (ROC) curves to determine the optimal diagnostic threshold scores above which women were likely to have clinically relevant urinary incontinence.ResultsThe optimal M-ISI diagnostic threshold scores were determined to be ≥ 3 for the stress urinary incontinence subdomain (area under the curve of 0.79), ≥ 5 for the urgency urinary incontinence subdomain (area under the curve of 0.88), and ≥ 7 for the Total M-ISI score (area under the curve of 0.89). The sensitivity and specificity of the M-ISI questionnaire for stress, urgency, and total urinary incontinence were 77% and 73%, 86% and 76%, and 84% and 75%, respectively.ConclusionsThe M-ISI may be used to screen for clinically relevant urinary incontinence with high sensitivity and specificity among women ages 35-64. A brief, self-administered tool such as the M-ISI can help health care providers identify and manage women with urinary incontinence.
- Published
- 2015
22. Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form
- Author
-
Skolarus, Ted A, Dunn, Rodney L, Sanda, Martin G, Chang, Peter, Greenfield, Thomas K, Litwin, Mark S, Wei, John T, Consortium, PROSTQA, Regan, Meredith, Hembroff, Larry, Hamstra, Dan, Dunn, Rodney, Northouse, Laurel, Wood, David, Klein, Eric A, Ciezki, Jay, Michalski, Jeff, Andriole, Gerald, Litwin, Mark, Saigal, Chris, Greenfield, Thomas, Pisters, Louis, Kuban, Deborah, Sandler, Howard, Hu, Jim, Kibel, Adam, Dahl, Douglas, Zietman, Anthony, Wagner, Andrew, and Kaplan, Irving
- Subjects
Prostate Cancer ,Urologic Diseases ,Cancer ,Aging ,Humans ,Male ,Prospective Studies ,Prostatic Neoplasms ,Quality of Life ,Records ,Surveys and Questionnaires ,PROSTQA Consortium ,Clinical Sciences ,Urology & Nephrology - Abstract
ObjectiveTo establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26). Although its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences [MIDs]).MethodsWe used distribution- and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, and vitality/hormonal) based on a prospective multi-institutional cohort of 1201 men treated for prostate cancer between 2003 and 2006 and followed up for 3 years after treatment. For the anchor-based approach, we compared within-subject and between-subject score changes for each domain to an external "anchor" measure of overall cancer treatment satisfaction.ResultsWe found the bowel and vitality/hormonal domains to have the lowest MID range (a 4-6 point change should be considered clinically relevant), whereas the sexual domain had the greatest MID values (10-12). Urinary incontinence appeared to have a greater MID range (6-9) than the urinary irritation/obstruction domain (5-7).ConclusionUsing 2 independent approaches, we established the MIDs for each EPIC-26 domain. A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.
- Published
- 2015
23. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
- Author
-
Prensner, John R, Zhao, Shuang, Erho, Nicholas, Schipper, Matthew, Iyer, Matthew K, Dhanasekaran, Saravana M, Magi-Galluzzi, Cristina, Mehra, Rohit, Sahu, Anirban, Siddiqui, Javed, Davicioni, Elai, Den, Robert B, Dicker, Adam P, Karnes, R Jeffrey, Wei, John T, Klein, Eric A, Jenkins, Robert B, Chinnaiyan, Arul M, and Feng, Felix Y
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Urologic Diseases ,Prostate Cancer ,Cancer ,Genetics ,Biotechnology ,Clinical Research ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Aetiology ,2.1 Biological and endogenous factors ,Aged ,Biomarkers ,Tumor ,Case-Control Studies ,Disease Progression ,Follow-Up Studies ,Gene Expression Profiling ,High-Throughput Nucleotide Sequencing ,Humans ,Lymphatic Metastasis ,Male ,Middle Aged ,Neoplasm Grading ,Neoplasm Invasiveness ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Prognosis ,Prostate-Specific Antigen ,Prostatectomy ,Prostatic Neoplasms ,RNA ,Long Noncoding ,Retrospective Studies ,Survival Rate ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundImproved clinical predictors for disease progression are needed for localised prostate cancer, since only a subset of patients develop recurrent or refractory disease after first-line treatment. Therefore, we undertook an unbiased analysis to identify RNA biomarkers associated with metastatic progression after prostatectomy.MethodsProstate cancer samples from patients treated with radical prostatectomy at three academic institutions were analysed for gene expression by a high-density Affymetrix GeneChip platform, encompassing more than 1 million genomic loci. In a discovery cohort, all protein-coding genes and known long non-coding RNAs were ranked by fold change in expression between tumours that subsequently metastasised versus those that did not. The top ranked gene was then validated for its prognostic value for metastatic progression in three additional independent cohorts. 95% of the gene expression assays were done in a Clinical Laboratory Improvements Amendments certified laboratory facility. All genes were assessed for their ability to predict metastatic progression by receiver-operating-curve area-under-the-curve analyses. Multivariate analyses were done for the primary endpoint of metastatic progression, with variables including Gleason score, preoperative prostate-specific antigen concentration, seminal vesicle invasion, surgical margin status, extracapsular extension, lymph node invasion, and expression of the highest ranked gene.Findings1008 patients were included in the study: 545 in the discovery cohort and 463 in the validation cohorts. The long non-coding RNA SChLAP1 was identified as the highest-ranked overexpressed gene in cancers with metastatic progression. Validation in three independent cohorts confirmed the prognostic value of SChLAP1 for metastatic progression. On multivariate modelling, SChLAP1 expression (high vs low) independently predicted metastasis within 10 years (odds ratio [OR] 2·45, 95% CI 1·70-3·53; p
- Published
- 2014
24. Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients
- Author
-
Shankar, Prasad R., Maturen, Katherine E., George, Arvin K., Borza, Tudor, Ellimoottil, Chandy, Montgomery, Jeffrey S., Wei, John T., Denton, Brian T., and Davenport, Matthew S.
- Published
- 2019
- Full Text
- View/download PDF
25. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator
- Author
-
Ankerst, Donna P., Goros, Martin, Tomlins, Scott A., Patil, Dattatraya, Feng, Ziding, Wei, John T., Sanda, Martin G., Gelfond, Jonathan, Thompson, Ian M., Leach, Robin J., and Liss, Michael A.
- Published
- 2019
- Full Text
- View/download PDF
26. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
- Author
-
Tosoian, Jeffrey J., Zhang, Yuping, Xiao, Lanbo, Xie, Cassie, Samora, Nathan L., Niknafs, Yashar S., Chopra, Zoey, Siddiqui, Javed, Zheng, Heng, Herron, Grace, Vaishampayan, Neil, Robinson, Hunter S., Arivoli, Kumaran, Trock, Bruce J., Ross, Ashley E., Morgan, Todd M., Palapattu, Ganesh S., Salami, Simpa S., Kunju, Lakshmi P., Tomlins, Scott A., Sokoll, Lori J., Chan, Daniel W., Srivastava, Sudhir, Feng, Ziding, Sanda, Martin G., Zheng, Yingye, Wei, John T., and Chinnaiyan, Arul M.
- Abstract
IMPORTANCE: Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grade PCa (ie, grade group [GG] 2 or greater). OBJECTIVE: To develop a multiplex urinary panel for high-grade PCa and validate its external performance relative to current guideline-endorsed biomarkers. DESIGN, SETTING, AND PARTICIPANTS: RNA sequencing analysis of 58 724 genes identified 54 markers of PCa, including 17 markers uniquely overexpressed by high-grade cancers. Gene expression and clinical factors were modeled in a new urinary test for high-grade PCa (MyProstateScore 2.0 [MPS2]). Optimal models were developed in parallel without prostate volume (MPS2) and with prostate volume (MPS2+). The locked models underwent blinded external validation in a prospective National Cancer Institute trial cohort. Data were collected from January 2008 to December 2020, and data were analyzed from November 2022 to November 2023. EXPOSURE: Protocolized blood and urine collection and transrectal ultrasound-guided systematic prostate biopsy. MAIN OUTCOMES AND MEASURES: Multiple biomarker tests were assessed in the validation cohort, including serum PSA alone, the Prostate Cancer Prevention Trial risk calculator, and the Prostate Health Index (PHI) as well as derived multiplex 2-gene and 3-gene models, the original 2-gene MPS test, and the 18-gene MPS2 models. Under a testing approach with 95% sensitivity for PCa of GG 2 or greater, measures of diagnostic accuracy and clinical consequences of testing were calculated. Cancers of GG 3 or greater were assessed secondarily. RESULTS: Of 761 men included in the development cohort, the median (IQR) age was 63 (58-68) years, and the median (IQR) PSA level was 5.6 (4.6-7.2) ng/mL; of 743 men included in the validation cohort, the median (IQR) age was 62 (57-68) years, and the median (IQR) PSA level was 5.6 (4.1-8.0) ng/mL. In the validation cohort, 151 (20.3%) had high-grade PCa on biopsy. Area under the receiver operating characteristic curve values were 0.60 using PSA alone, 0.66 using the risk calculator, 0.77 using PHI, 0.76 using the derived multiplex 2-gene model, 0.72 using the derived multiplex 3-gene model, and 0.74 using the original MPS model compared with 0.81 using the MPS2 model and 0.82 using the MPS2+ model. At 95% sensitivity, the MPS2 model would have reduced unnecessary biopsies performed in the initial biopsy population (range for other tests, 15% to 30%; range for MPS2, 35% to 42%) and repeat biopsy population (range for other tests, 9% to 21%; range for MPS2, 46% to 51%). Across pertinent subgroups, the MPS2 models had negative predictive values of 95% to 99% for cancers of GG 2 or greater and of 99% for cancers of GG 3 or greater. CONCLUSIONS AND RELEVANCE: In this study, a new 18-gene PCa test had higher diagnostic accuracy for high-grade PCa relative to existing biomarker tests. Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers. These data support use of this new PCa biomarker test in patients with elevated PSA levels to reduce the potential harms of PCa screening while preserving its long-term benefits.
- Published
- 2024
- Full Text
- View/download PDF
27. The Michigan incontinence symptom index (M‐ISI): A clinical measure for type, severity, and bother related to urinary incontinence
- Author
-
Suskind, Anne M, Dunn, Rodney L, Morgan, Daniel M, DeLancey, John OL, McGuire, Edward J, and Wei, John T
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Urologic Diseases ,Clinical Research ,Adult ,Aged ,Aged ,80 and over ,Female ,Humans ,Male ,Middle Aged ,Psychometrics ,Quality of Life ,Reproducibility of Results ,Severity of Illness Index ,Surveys and Questionnaires ,Symptom Assessment ,Urinary Incontinence ,Young Adult ,quality of life ,urge urinary incontinence ,stress urinary incontinence ,bother ,impact ,pad use ,Urology & Nephrology ,Clinical sciences - Abstract
AimsTo develop a clinically relevant, easy to use, and validated instrument for assessing severity and bother related to urinary incontinence.MethodsSurvey items were piloted and refined following psychometric principles in five separate patient cohorts. Patient and expert endorsement of items, factor analyses, Spearman rank correlations and response distributions were employed for item selection. Formal reliability and validity evaluation were conducted for the final questionnaire items.ResultsExpert physicians and patient focus groups confirmed face and content validity for the measure. A 10-item measure called the Michigan Incontinence Symptom Index (M-ISI) was developed with two domains: a Total M-ISI Domain consisting of subdomains for stress urinary incontinence, urgency urinary incontinence, and pad use, and a Bother Domain. High construct validity was demonstrated with a Cronbach's alpha for the Total M-ISI Domain (items 1-8) of 0.90 and for the Bother Domain (items 9-10) of 0.82. Cronbach's alpha for the subdomains were all > 0.85. Construct validity, convergent and divergent validity, internal discriminant validity, and predictive validity were all robust. The minimally important difference for the measure was determined to be 4 points (out of 32) for the Total M-ISI Severity Domain, and 1-2 points (out of 8-12) for the individual subdomains.ConclusionsThe M-ISI is a parsimonious measure that has established reliability and validity on several levels and complements current clinical evaluative methods for patients with urinary incontinence.
- Published
- 2014
28. Satisfaction with Information Used to Choose Prostate Cancer Treatment
- Author
-
Gilbert, Scott M, Sanda, Martin G, Dunn, Rodney L, Greenfield, Thomas K, Hembroff, Larry, Klein, Eric, Saigal, Christopher S, Pisters, Louis, Michalski, Jeff, Sandler, Howard M, Litwin, Mark S, and Wei, John T
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Aging ,Urologic Diseases ,Rehabilitation ,Prostate Cancer ,Clinical Research ,Prevention ,Behavioral and Social Science ,Management of diseases and conditions ,7.1 Individual care needs ,Adult ,Aged ,Aged ,80 and over ,Choice Behavior ,Consumer Health Information ,Humans ,Male ,Middle Aged ,Patient Satisfaction ,Prospective Studies ,Prostatic Neoplasms ,prostate ,prostatic neoplasms ,consumer health information ,consumer satisfaction ,questionnaires - Abstract
PurposeAfter being diagnosed with prostate cancer men must assimilate information regarding the cancer. Satisfaction with information reflects the evaluation of information sources used before treatment to select a therapy. We describe the use and helpfulness of several information sources available to prostate cancer survivors. We also identified factors associated with satisfaction with information.Materials and methodsA total of 1,204 men with newly diagnosed prostate cancer were enrolled in the prospective, multicenter Prostate Cancer Outcomes and Satisfaction with Therapy Quality Assessment study. The validated satisfaction with information domain of the Service Satisfaction Scale-Cancer was administered to subjects 2 months after treatment. The relationship between several factors, such as demographics, socioeconomic factors, cancer severity and types of information sources, and satisfaction with information were evaluated using multiple regression.ResultsSources of information endorsed by subjects varied by race, education and study site. The most helpful sources were treatment description by the treating physician (33.1%), Internet sites (18.9%) and books (18.1%). In multiple variable models patient age (p = 0.005) and information provided by the physician regarding outcomes in their patients (p = 0.01) were independently associated with patient satisfaction with the information provided.ConclusionsVarious information sources were used and endorsed as helpful by subjects, although results for physician patients was the only source independently associated with satisfaction with information. Providing patients with information about possible or expected courses of care and outcomes may improve satisfaction.
- Published
- 2014
29. Measuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice
- Author
-
Chipman, Jonathan J, Sanda, Martin G, Dunn, Rodney L, Wei, John T, Litwin, Mark S, Crociani, Catrina M, Regan, Meredith M, Chang, Peter, and Consortium, PROST-QA
- Subjects
Cancer ,Prostate Cancer ,Urologic Diseases ,Clinical Research ,Behavioral and Social Science ,Management of diseases and conditions ,7.1 Individual care needs ,Good Health and Well Being ,Humans ,Intestinal Diseases ,Longitudinal Studies ,Male ,Middle Aged ,Postoperative Complications ,Predictive Value of Tests ,Prospective Studies ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Sexual Dysfunction ,Physiological ,Surveys and Questionnaires ,prostate ,prostatic neoplasms ,quality of life ,questionnaires ,outcome assessment ,PROST-QA Consortium - Abstract
PurposeWe expanded the clinical usefulness of EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) by evaluating its responsiveness to health related quality of life changes, defining the minimally important differences for an individual patient change in each domain and applying it to a sexual outcome prediction model.Materials and methodsIn 1,201 subjects from a previously described multicenter longitudinal cohort we modeled the EPIC-CP domain scores of each treatment group before treatment, and at short-term and long-term followup. We considered a posttreatment domain score change from pretreatment of 0.5 SD or greater clinically significant and p ≤ 0.01 statistically significant. We determined the domain minimally important differences using the pooled 0.5 SD of the 2, 6, 12 and 24-month posttreatment changes from pretreatment values. We then recalibrated an EPIC-CP based nomogram model predicting 2-year post-prostatectomy functional erection from that developed using EPIC-26.ResultsFor each health related quality of life domain EPIC-CP was sensitive to similar posttreatment health related quality of life changes with time, as was observed using EPIC-26. The EPIC-CP minimally important differences in changes in the urinary incontinence, urinary irritation/obstruction, bowel, sexual and vitality/hormonal domains were 1.0, 1.3, 1.2, 1.6 and 1.0, respectively. The EPIC-CP based sexual prediction model performed well (AUC 0.76). It showed robust agreement with its EPIC-26 based counterpart with 10% or less predicted probability differences between models in 95% of individuals and a mean ± SD difference of 0.0 ± 0.05 across all individuals.ConclusionsEPIC-CP is responsive to health related quality of life changes during convalescence and it can be used to predict 2-year post-prostatectomy sexual outcomes. It can facilitate shared medical decision making and patient centered care.
- Published
- 2014
30. Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice
- Author
-
Singhal, Udit, primary, Hollenbeck, Brent K., additional, Kaffenberger, Samuel D., additional, Salami, Simpa S., additional, George, Arvin K., additional, Skolarus, Ted A., additional, Montgomery, Jeffrey S., additional, Wittmann, Daniela A., additional, Miller, David C., additional, Wei, John T., additional, Palapattu, Ganesh S., additional, Montie, James E., additional, Dunn, Rodney L., additional, and Morgan, Todd M., additional
- Published
- 2023
- Full Text
- View/download PDF
31. Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study
- Author
-
Gay, Hiram Alberto, Michalski, Jeff M, Hamstra, Daniel A, Wei, John T, Dunn, Rodney L, Klein, Eric A, Sandler, Howard M, Saigal, Chris, Litwin, Mark, Kuban, Deborah, Hembroff, Larry, Chang, Peter, Sanda, Martin G, and Consortium, PROSTQA
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Urologic Diseases ,Aging ,Prostate Cancer ,Cancer ,Biopsy ,Needle ,Humans ,Image-Guided Biopsy ,Male ,Prospective Studies ,Prostatic Neoplasms ,Quality of Life ,Unnecessary Procedures ,PROSTQA Consortium ,Urology & Nephrology ,Clinical sciences - Abstract
ObjectiveTo evaluate the immediate effects of neoadjuvant androgen deprivation therapy (NADT) on health-related quality of life (HRQOL) among patients undergoing radiation therapy (RT) for newly diagnosed prostate cancer.MethodsThe Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium is a prospective multi-institutional study. HRQOL is measured with the Expanded Prostate Cancer Index Composite-26 questionnaire. Differences in patient-reported HRQOL were observed between pretreatment and 2 months after NADT start (and before definitive RT) with significant differences evaluated by paired t test.ResultsFrom among 450 patients who completed the Expanded Prostate Cancer Index Composite-26 before and 2 months after NADT start, 71 received NADT before proceeding with definitive RT. Patients receiving NADT experienced significant impairment in vitality/hormonal (P
- Published
- 2013
32. Potential Savings in Medicare Part D for Common Urological Conditions
- Author
-
Kirk, Peter S., Borza, Tudor, Dupree, James M., Wei, John T., Ellimoottil, Chad, Caram, Megan E.V., Burkhardt, Mary, Heidelbaugh, Joel J., Hollenbeck, Brent K., and Skolarus, Ted A.
- Published
- 2018
- Full Text
- View/download PDF
33. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies
- Author
-
Golan, Ron, Bernstein, Adrien, Sedrakyan, Art, Daskivich, Timothy J., Du, Dongyi T., Ehdaie, Behfar, Fisher, Benjamin, Gorin, Michael A., Grunberger, Ivan, Hunt, Bradley, Jiang, Hongying H., Kim, Hyung L., Marinac-Dabic, Danica, Marks, Leonard S., McClure, Timothy D., Montgomery, Jeffrey S., Parekh, Dipen J., Punnen, Sanoj, Scionti, Stephen, Viviano, Charles J., Wei, John T., Wenske, Sven, Wysock, James S., Rewcastle, John, Carol, Mark, Oczachowski, Marc, and Hu, Jim C.
- Published
- 2018
- Full Text
- View/download PDF
34. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life
- Author
-
Jackson, William C., Dess, Robert T., Litzenberg, Dale W., Li, Pin, Schipper, Matthew, Rosenthal, Seth A., Chang, Garrick C., Horwitz, Eric M., Price, Robert A., Michalski, Jeff M., Gay, Hiram A., Wei, John T., Feng, Mary, Feng, Felix Y., Sandler, Howard M., Wallace, Robert E., Spratt, Daniel E., and Hamstra, Daniel A.
- Published
- 2018
- Full Text
- View/download PDF
35. Differential Adoption of Laser Prostatectomy for Treatment of Benign Prostatic Hyperplasia
- Author
-
Schroeck, Florian R, Hollingsworth, John M, Hollenbeck, Brent K, Jacobs, Bruce L, Suskind, Anne M, Sarma, Aruna V, and Wei, John T
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Urologic Diseases ,Adult ,Analysis of Variance ,Florida ,Healthcare Disparities ,Humans ,Insurance ,Health ,Laser Therapy ,Male ,Medicaid ,Middle Aged ,Multivariate Analysis ,Prostatectomy ,Prostatic Hyperplasia ,Socioeconomic Factors ,Transurethral Resection of Prostate ,United States ,Urology & Nephrology ,Clinical sciences - Abstract
ObjectiveTo evaluate whether socioeconomic environment affects the adoption of new laser technology for treatment of benign prostatic hyperplasia (BPH).MethodsUsing all payer data, we identified all discharges for laser prostatectomy or transurethral resection of the prostate (TURP) performed in Florida (2001-2009). We determined whether or not each of 114 healthcare markets (Hospital Service Areas) offered laser prostatectomy or TURP and assessed the market-level socioeconomic environment using a previously described ZIP code-based summary score. We used generalized estimating equations to examine the association of socioeconomic environment with offering laser prostatectomy or TURP, adjusting for additional market characteristics.ResultsBetter socioeconomic environment was associated with offering laser prostatectomy (odds ratio 1.21 for each 1 point increase in summary score, 95% confidence interval 1.08-1.35, P
- Published
- 2013
36. Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
- Author
-
Lin, Daniel W, Newcomb, Lisa F, Brown, Elissa C, Brooks, James D, Carroll, Peter R, Feng, Ziding, Gleave, Martin E, Lance, Raymond S, Sanda, Martin G, Thompson, Ian M, Wei, John T, Nelson, Peter S, and Investigators, for the Canary Prostate Active Surveillance Study
- Subjects
Prostate Cancer ,Aging ,Prevention ,Clinical Research ,Urologic Diseases ,Cancer ,Adult ,Aged ,Aged ,80 and over ,Antigens ,Neoplasm ,Biomarkers ,Tumor ,Epidemiological Monitoring ,Humans ,Male ,Middle Aged ,Neoplasm Grading ,Oncogene Proteins ,Fusion ,Prospective Studies ,Prostate ,Prostatic Neoplasms ,ROC Curve ,Reference Values ,Statistics ,Nonparametric ,Tumor Burden ,Canary Prostate Active Surveillance Study Investigators ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeActive surveillance is used to manage low-risk prostate cancer. Both PCA3 and TMPRSS2:ERG are promising biomarkers that may be associated with aggressive disease. This study examines the correlation of these biomarkers with higher cancer volume and grade determined at the time of biopsy in an active surveillance cohort.Experimental designUrine was collected after digital rectal examination prospectively as part of the multi-institutional Canary Prostate Active Surveillance Study (PASS). PCA3 and TMPRSS2:ERG levels were analyzed in urine collected at study entry. Biomarker scores were correlated to clinical and pathologic variables.ResultsIn 387 men, both PCA3 and TMPRSS2:ERG scores were significantly associated with higher volume disease. For a negative repeat biopsy, and 1% to 10%, 11% to 33%, 34% or more positive cores, median PCA3, and TMPRSS2:ERG scores increased incrementally (P < 0.005). Both PCA3 and TMPRSS2:ERG scores were also significantly associated with the presence of high-grade disease. For a negative repeat biopsy, Gleason 6 and Gleason ≥7 cancers, the median PCA3, and TMPRSS2:ERG scores also increased incrementally (P = 0.02 and P = 0.001, respectively). Using the marker scores as continuous variables, the ORs for a biopsy in which cancer was detected versus a negative repeat biopsy (ref) on modeling was 1.41 (95% CI: 1.07-1.85), P = 0.01 for PCA3 and 1.28 (95% CI: 1.10-1.49), P = 0.001 for TMPRSS2:ERG.ConclusionsFor men on active surveillance, both PCA3 and TMPRSS2:ERG seem to stratify the risk of having aggressive cancer as defined by tumor volume or Gleason score.
- Published
- 2013
37. Prediction of Erectile Function Following Treatment for Prostate Cancer
- Author
-
Alemozaffar, Mehrdad, Regan, Meredith M, Cooperberg, Matthew R, Wei, John T, Michalski, Jeff M, Sandler, Howard M, Hembroff, Larry, Sadetsky, Natalia, Saigal, Christopher S, Litwin, Mark S, Klein, Eric, Kibel, Adam S, Hamstra, Daniel A, Pisters, Louis L, Kuban, Deborah A, Kaplan, Irving D, Wood, David P, Ciezki, Jay, Dunn, Rodney L, Carroll, Peter R, and Sanda, Martin G
- Subjects
Cancer ,Urologic Diseases ,Rehabilitation ,Prostate Cancer ,Clinical Research ,Aging ,Aged ,Brachytherapy ,Erectile Dysfunction ,Forecasting ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Models ,Theoretical ,Outcome Assessment ,Health Care ,Penile Erection ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Radiation Injuries ,Medical and Health Sciences ,General & Internal Medicine - Abstract
ContextSexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are lacking.ObjectiveTo predict long-term erectile function following prostate cancer treatment based on individual patient and treatment characteristics.DesignPretreatment patient characteristics, sexual HRQOL, and treatment details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; enrolled from 2003 through 2006), were used to develop models predicting erectile function 2 years after treatment. A community-based cohort (community-based Cancer of the Prostate Strategic Urologic Research Endeavor [CaPSURE]; enrolled 1995 through 2007) externally validated model performance. Patients in US academic and community-based practices whose HRQOL was measured pretreatment (N = 1201) underwent follow-up after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. Sexual outcomes among men completing 2 years' follow-up (n = 1027) were used to develop models predicting erectile function that were externally validated among 1913 patients in a community-based cohort.Main outcome measuresPatient-reported functional erections suitable for intercourse 2 years following prostate cancer treatment.ResultsTwo years after prostate cancer treatment, 368 (37% [95% CI, 34%-40%]) of all patients and 335 (48% [95% CI, 45%-52%]) of those with functional erections prior to treatment reported functional erections; 531 (53% [95% CI, 50%-56%]) of patients without penile prostheses reported use of medications or other devices for erectile dysfunction. Pretreatment sexual HRQOL score, age, serum prostate-specific antigen level, race/ethnicity, body mass index, and intended treatment details were associated with functional erections 2 years after treatment. Multivariable logistic regression models predicting erectile function estimated 2-year function probabilities from as low as 10% or less to as high as 70% or greater depending on the individual's pretreatment patient characteristics and treatment details. The models performed well in predicting erections in external validation among CaPSURE cohort patients (areas under the receiver operating characteristic curve, 0.77 [95% CI, 0.74-0.80] for prostatectomy; 0.87 [95% CI, 0.80-0.94] for external radiotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy).ConclusionStratification by pretreatment patient characteristics and treatment details enables prediction of erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.
- Published
- 2011
38. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life
- Author
-
Regan, Meredith, Hembroff, Larry, Wei, John T., Hamstra, Dan, Dunn, Rodney, Northouse, Laurel, Wood, David, Klein, Eric A., Ciezki, Jay, Michalski, Jeff, Andriole, Gerald, Litwin, Mark S., Saigal, Christopher, Greenfield, Thomas, Pisters, Louis, Kuban, Deborah, Sandler, Howard, Hu, Jim, Kibel, Adam, Dahl, Douglas, Zietman, Anthony, Chang, Peter, Kaplan, Irving, Wagner, Andrew, Sanda, Martin G., Gay, Hiram A., Liu, Jingxia, Wu, Ningying, Hamstra, Daniel A., Dunn, Rodney L., Sandler, Howard M., Saigal, Christopher S., Kuban, Deborah A., Regan, Meredith M., and Michalski, Jeff M.
- Published
- 2017
- Full Text
- View/download PDF
39. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
- Author
-
Wei, John T., primary, Barocas, Daniel, additional, Carlsson, Sigrid, additional, Coakley, Fergus, additional, Eggener, Scott, additional, Etzioni, Ruth, additional, Fine, Samson W., additional, Han, Misop, additional, Kim, Sennett K., additional, Kirkby, Erin, additional, Konety, Badrinath R., additional, Miner, Martin, additional, Moses, Kelvin, additional, Nissenberg, Merel G., additional, Pinto, Peter A., additional, Salami, Simpa S., additional, Souter, Lesley, additional, Thompson, Ian M., additional, and Lin, Daniel W., additional
- Published
- 2023
- Full Text
- View/download PDF
40. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy
- Author
-
Wei, John T., primary, Barocas, Daniel, additional, Carlsson, Sigrid, additional, Coakley, Fergus, additional, Eggener, Scott, additional, Etzioni, Ruth, additional, Fine, Samson W., additional, Han, Misop, additional, Kim, Sennett K., additional, Kirkby, Erin, additional, Konety, Badrinath R., additional, Miner, Martin, additional, Moses, Kelvin, additional, Nissenberg, Merel G., additional, Pinto, Peter A., additional, Salami, Simpa S., additional, Souter, Lesley, additional, Thompson, Ian M., additional, and Lin, Daniel W., additional
- Published
- 2023
- Full Text
- View/download PDF
41. Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer
- Author
-
Tosoian, Jeffrey J., primary, Zhang, Yuping, additional, Xiao, Lanbo, additional, Xie, Cassie, additional, Samora, Nathan L., additional, Niknafs, Yashar S., additional, Chopra, Zoey, additional, Siddiqui, Javed, additional, Zheng, Heng, additional, Herron, Grace, additional, Vaishampayan, Neil, additional, Arivoli, Kumaran, additional, Trock, Bruce J., additional, Ross, Ashley E., additional, Morgan, Todd M., additional, Palapattu, Ganesh S., additional, Salami, Simpa S., additional, Kunju, Lakshmi P., additional, Zheng, Yingye, additional, Wei, John T., additional, and Chinnaiyan, Arul M., additional
- Published
- 2023
- Full Text
- View/download PDF
42. Supplementary Table 1 from Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer
- Author
-
Birnbaum, Jeanette K., primary, Feng, Ziding, primary, Gulati, Roman, primary, Fan, Jing, primary, Lotan, Yair, primary, Wei, John T., primary, and Etzioni, Ruth, primary
- Published
- 2023
- Full Text
- View/download PDF
43. Supplementary Data from Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States
- Author
-
Mosquera, Juan-Miguel, primary, Mehra, Rohit, primary, Regan, Meredith M., primary, Perner, Sven, primary, Genega, Elizabeth M., primary, Bueti, Gerri, primary, Shah, Rajal B., primary, Gaston, Sandra, primary, Tomlins, Scott A., primary, Wei, John T., primary, Kearney, Michael C., primary, Johnson, Laura A., primary, Tang, Jeffrey M., primary, Chinnaiyan, Arul M., primary, Rubin, Mark A., primary, and Sanda, Martin G., primary
- Published
- 2023
- Full Text
- View/download PDF
44. Data from Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer
- Author
-
Birnbaum, Jeanette K., primary, Feng, Ziding, primary, Gulati, Roman, primary, Fan, Jing, primary, Lotan, Yair, primary, Wei, John T., primary, and Etzioni, Ruth, primary
- Published
- 2023
- Full Text
- View/download PDF
45. Supplementary Figures 1-3 from Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
- Author
-
Lin, Daniel W., primary, Newcomb, Lisa F., primary, Brown, Elissa C., primary, Brooks, James D., primary, Carroll, Peter R., primary, Feng, Ziding, primary, Gleave, Martin E., primary, Lance, Raymond S., primary, Sanda, Martin G., primary, Thompson, Ian M., primary, Wei, John T., primary, and Nelson, Peter S., primary
- Published
- 2023
- Full Text
- View/download PDF
46. Data from A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
- Author
-
Laxman, Bharathi, primary, Morris, David S., primary, Yu, Jianjun, primary, Siddiqui, Javed, primary, Cao, Jie, primary, Mehra, Rohit, primary, Lonigro, Robert J., primary, Tsodikov, Alex, primary, Wei, John T., primary, Tomlins, Scott A., primary, and Chinnaiyan, Arul M., primary
- Published
- 2023
- Full Text
- View/download PDF
47. Supplementary Figure 1 Legend from A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
- Author
-
Laxman, Bharathi, primary, Morris, David S., primary, Yu, Jianjun, primary, Siddiqui, Javed, primary, Cao, Jie, primary, Mehra, Rohit, primary, Lonigro, Robert J., primary, Tsodikov, Alex, primary, Wei, John T., primary, Tomlins, Scott A., primary, and Chinnaiyan, Arul M., primary
- Published
- 2023
- Full Text
- View/download PDF
48. Supplementary Table 1 from A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
- Author
-
Laxman, Bharathi, primary, Morris, David S., primary, Yu, Jianjun, primary, Siddiqui, Javed, primary, Cao, Jie, primary, Mehra, Rohit, primary, Lonigro, Robert J., primary, Tsodikov, Alex, primary, Wei, John T., primary, Tomlins, Scott A., primary, and Chinnaiyan, Arul M., primary
- Published
- 2023
- Full Text
- View/download PDF
49. Supplementary Table 3 from A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
- Author
-
Laxman, Bharathi, primary, Morris, David S., primary, Yu, Jianjun, primary, Siddiqui, Javed, primary, Cao, Jie, primary, Mehra, Rohit, primary, Lonigro, Robert J., primary, Tsodikov, Alex, primary, Wei, John T., primary, Tomlins, Scott A., primary, and Chinnaiyan, Arul M., primary
- Published
- 2023
- Full Text
- View/download PDF
50. Supplementary Figure 1 from A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
- Author
-
Laxman, Bharathi, primary, Morris, David S., primary, Yu, Jianjun, primary, Siddiqui, Javed, primary, Cao, Jie, primary, Mehra, Rohit, primary, Lonigro, Robert J., primary, Tsodikov, Alex, primary, Wei, John T., primary, Tomlins, Scott A., primary, and Chinnaiyan, Arul M., primary
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.